Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

(2018) Liana K. Billings et al.   DIABETES CARE

Deintensification of hypoglycaemic medications-use of a systematic review approach to highlight safety concerns in older people with type 2 diabetes

(2018) A.H. Abdelhafiz et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Clinical inertia versus overtreatment in glycaemic management

(2018) Kamlesh Khunti et al.   Lancet Diabetes & Endocrinology

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries

(2017) Matthew L. Maciejewski et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

(2017) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Deintensification Is Uncommon in Adults With Type 2 Diabetes Mellitus

(2017) Finlay A. McAlister et al.   Circulation-Cardiovascular Quality and Outcomes

A Practical Review of C-Peptide Testing in Diabetes

(2017) Emma Leighton et al.   Diabetes Therapy

A Practical Review of C-Peptide Testing in Diabetes

(2017) Emma Leighton et al.   Diabetes Therapy

Treated glycosylated hemoglobin levels in individuals with diabetes mellitus vary little by health status

(2016) Finlay A. McAlister et al.   MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simplification of Insulin Regimen in Older Adults and Risk of Hypoglycemia

(2016) Medha N. Munshi et al.   JAMA Internal Medicine

Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149

(2015) Silvio E. Inzucchi et al.   DIABETES CARE

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

(2015) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus

(2015) Jeremy B. Sussman et al.   JAMA Internal Medicine

Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control

(2015) Kasia J. Lipska et al.   JAMA Internal Medicine

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

(2014) Stephen C L Gough et al.   Lancet Diabetes & Endocrinology

Assessing Potential Glycemic Overtreatment in Persons at Hypoglycemic Risk

(2013) Chin-Lin Tseng et al.   JAMA Internal Medicine

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

(2008) Priscilla Hollander et al.   CLINICAL THERAPEUTICS